Jump to content

User:Mr. Ibrahem/Fedratinib

From Wikipedia, the free encyclopedia
< User:Mr. Ibrahem

This is the current revision of this page, as edited by Mr. Ibrahem (talk | contribs) at 23:45, 22 March 2024 (from https://mdwiki.org/wiki/Fedratinib). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Mr. Ibrahem/Fedratinib
Clinical data
Trade namesInrebic
Other namesFedratinib hydrochloride, SAR302503; TG101348
AHFS/Drugs.comMonograph
License data
Routes of
administration		By mouth
Drug classAntineoplastic agent (inhibitor of Janus kinase 2 (JAK-2) and FLT-3)[1]
Legal status
Legal status
Identifiers
  • N-tert-Butyl-3-{5-methyl-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-ylamino}-benzenesulfonamide
Chemical and physical data
FormulaC27H36N6O3S
Molar mass524.68 g·mol−1
3D model (JSmol)
Density1.247 ± 0.06 g/cm3
  • CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4
  • InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)
  • Key:JOOXLOJCABQBSG-UHFFFAOYSA-N
 ☒NcheckY (what is this?)

Fedratinib, sold under the brand name Inrebic, is a medication used to treat myelofibrosis.[1] This includes primary myelofibrosis, post-polycythaemia vera myelofibrosis, and post-essential thrombocythaemia myelofibrosis.[3] It is used when there is an enlarged spleen or other symptoms.[3] It is taken by mouth.[1]

Common side effects include diarrhea, nausea, low red blood cells, and low platelets.[3] Other side effects may include encephalopathy.[1] It is an inhibitor of Janus kinase 2 (JAK-2) and FLT-3.[1]

Fedratinib was approved for medical use in the United States in 2019 and Europe in 2021.[1][3] In the United Kingdom a month of medication costs the NHS about £6,100 as of 2021.[4] This amount in the United States costs about 21,300 USD.[5]

References[edit]

  1. ^ a b c d e f g h "Fedratinib Monograph for Professionals". Drugs.com. Retrieved 10 December 2021.
  2. ^ "Inrebic- fedratinib hydrochloride capsule". DailyMed. Archived from the original on 6 April 2021. Retrieved 3 March 2021.
  3. ^ a b c d e f "Inrebic EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 7 March 2021. Retrieved 3 March 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ "Fedratinib". SPS - Specialist Pharmacy Service. 19 March 2018. Archived from the original on 11 December 2021. Retrieved 10 December 2021.
  5. ^ "Fedratinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 10 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Fedratinib&oldid=1215079663"